Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology is a strong, well-positioned company with a promising pipeline of small-molecule medicines designed to target cancer signaling pathways. Their initial sales from KOMZIFTI, the first and only once-daily, oral menin inhibitor for r/r NPM1-m AML, were $2.1 million in addition to $195 million in non-dilutive milestone payments and an estimated $15 to $17 million in collaboration revenue in the same period. With a solid cash balance of $667 million at the end of YE25 and key anticipated milestones and catalysts expected for 2026, they are well equipped to execute on both clinical and commercial objectives. This, coupled with their recent FDA approval for KOMZIFTI and strategic commercial strategy, leads us to believe that Kura Oncology has a promising future ahead.

Kura Oncology is facing a challenging outlook due to a lack of significant data and a highly competitive market for its targeted cancer therapies, including its lead product candidate, darolifarnib. With the expected initiation of expansion cohorts and data presentations in the first half of 2026, investors may be hesitant to make a bet on the company until there is more positive data and a clearer path to market success. In addition, the pricing strategy for its recently approved drug, Revuforj, may not meet expectations with a WAC of approximately $58,000, indicating potential struggles with reimbursement and competition in the market. Overall, the company's future success may be hindered by its current challenges and limitations, making it a risky investment at this time.